Transition Bio, Voyager Therapeutics Partner for ALS, FTD Drug Discovery

Transition Bio and Voyager Therapeutics have entered into a drug discovery collaboration and license option agreement to develop novel small molecules for treating ALS and FTD with TDP-43 pathology. Transition Bio will be responsible for discovery and optimization until a development candidate is nominated, at which point Voyager will have an option to license the compound. This partnership aims to leverage biomolecular condensates to address traditionally undruggable targets in neurodegenerative diseases.